• Interim results from Cohort 1 show negligible scar formation with average VSS score of 1.1/13 at 12 months
• TetraDerm is easily applied during surgeries and transforms into a cohesive gel to support natural healing
• Represents a critical milestone in the commercial pathway for TetraDerm as the company targets the $US2.1 billion wound closure market

Tetratherix Limited (ASX: TTX) is pleased to announce the interim performance results from the clinical use of its scar prevention product, TetraDerm, on patients undergoing surgeries to remove skin lesions. Interim results from Cohort 1 of the TetraDerm study show that when the product is laid between layers of skin tissue before final wound closure, the subsequent scar formed at the site was minimal. The results indicate an average VSS score of 1.8/13 at 3 months, decreasing to 1.1/13 at 12 months. This demonstrates that the scarring is restricted to just 13% at 3 months and further reduced to 8% after 12 months. TetraDerm is easily applied during surgeries and has a unique mode of action that relies on the technology's ability to transform from a liquid to a cohesive gel in the body, which supports natural healing. This interim result is a critical milestone in Tetratherix's commercial pathway for TetraDerm, as the company continues to collect the clinical evidence required to access the $US2.1 billion wound closure market. The company has completed Cohort 1, is currently progressing Cohort 2, and has begun enrolment for Cohort 3, which will assess the product's performance in complex plastic and reconstructive surgeries. Tetratherix is engaging with potential commercial partners to bring TetraDerm to market, with the goal of establishing it as a new global standard in surgical outcomes.

Tetratherix is moving at a velocity that traditional medtech companies often find uncomfortable, having already moved into the final cohort for complex reconstructive surgeries. The company is systematically de-risking a massive commercial opportunity in the $US2.1 billion wound closure market, and its focus is locked on the execution of the strategy that will bring TetraDerm to every operating theatre in the world.